Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.

Torphy TJ, Allen J, Cantin AM, Konstan MW, Accurso FJ, Joseloff E, Ratjen FA, Chmiel JF; Antiinflammatory Therapy Working Group.

Ann Am Thorac Soc. 2015 Sep;12(9):1398-406. doi: 10.1513/AnnalsATS.201506-361OT. Review.

PMID:
26146892
2.

Biopharmaceutical therapeutics for asthma remodeling.

Das AM, Griswold DE, Torphy TJ, Li L.

Curr Pharm Des. 2006;12(25):3233-40. Review.

PMID:
17020531
4.

Coming of age: anti-cytokine therapies.

Song XY, Torphy TJ, Griswold DE, Shealy D.

Mol Interv. 2002 Feb;2(1):36-46. Review.

PMID:
14993360
5.

What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases.

Li L, Das AM, Torphy TJ, Griswold DE.

Pulm Pharmacol Ther. 2002;15(5):409-16. Review.

PMID:
12406662
6.

Monoclonal antibodies as a strategy for pulmonary diseases.

Torphy TJ, Li L, Griswold DE.

Curr Opin Pharmacol. 2001 Jun;1(3):265-71. Review.

PMID:
11712750
7.

Tumor necrosis factor-alpha-induced secretion of RANTES and interleukin-6 from human airway smooth-muscle cells. Modulation by cyclic adenosine monophosphate.

Ammit AJ, Hoffman RK, Amrani Y, Lazaar AL, Hay DW, Torphy TJ, Penn RB, Panettieri RA Jr.

Am J Respir Cell Mol Biol. 2000 Dec;23(6):794-802.

PMID:
11104733
8.

Phosphodiesterases: the journey towards therapeutics.

Torphy TJ, Page C.

Trends Pharmacol Sci. 2000 May;21(5):157-9. No abstract available.

PMID:
10885973
9.

Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, Barnette MS.

Br J Pharmacol. 1999 Dec;128(7):1393-8.

10.

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.

Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, Compton CH.

Pulm Pharmacol Ther. 1999;12(2):131-5. Review. No abstract available.

PMID:
10373396
11.

Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation.

Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, Madrenas J.

J Immunol. 1999 Feb 15;162(4):2016-23.

12.

Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig.

Underwood DC, Bochnowicz S, Osborn RR, Kotzer CJ, Luttmann MA, Hay DW, Gorycki PD, Christensen SB, Torphy TJ.

J Pharmacol Exp Ther. 1998 Dec;287(3):988-95.

13.

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ.

J Pharmacol Exp Ther. 1998 Nov;287(2):705-11.

14.

Critical role of conserved histidine pairs HNXXH and HDXXH in recombinant human phosphodiesterase 4A.

Omburo GA, Jacobitz S, Torphy TJ, Colman RW.

Cell Signal. 1998 Jul;10(7):491-7.

PMID:
9754717
15.

1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinski JM, DeWolf WE Jr, Barnette MS, Underwood DC, Griswold DE, Cieslinski LB, Burman M, Bochnowicz S, Osborn RR, Manning CD, Grous M, Hillegas LM, Bartus JO, Ryan MD, Eggleston DS, Haltiwanger RC, Torphy TJ.

J Med Chem. 1998 Mar 12;41(6):821-35.

PMID:
9526558
16.

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

Torphy TJ.

Am J Respir Crit Care Med. 1998 Feb;157(2):351-70. Review. No abstract available.

PMID:
9476844
17.

SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.

Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, Torphy TJ.

J Pharmacol Exp Ther. 1998 Jan;284(1):420-6.

18.

Re-classification of NSAIDs.

Griswold DE, Ruffolo RR, Poste G, Torphy TJ.

Trends Pharmacol Sci. 1997 Sep;18(9):311-2. No abstract available.

PMID:
9345847
19.

Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A.

Jacobitz S, Ryan MD, McLaughlin MM, Livi GP, DeWolf WE Jr, Torphy TJ.

Mol Pharmacol. 1997 Jun;51(6):999-1006.

20.

Mechanisms of adaptive supersensitivity: correlation of guinea pig atrial supersensitivity with modifications in adenylyl cyclase activity.

Roberts MI, Stadel JM, Torphy TJ, Fleming WW, Taylor DA.

Biochem Pharmacol. 1997 Feb 7;53(3):347-56.

PMID:
9065738
21.

Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.

Willette RN, Shiloh AO, Sauermelch CF, Sulpizio A, Michell MP, Cieslinski LB, Torphy TJ, Ohlstein EH.

J Cereb Blood Flow Metab. 1997 Feb;17(2):210-9.

PMID:
9040501
22.
23.

The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig.

Underwood DC, Matthews JK, Osborn RR, Bochnowicz S, Torphy TJ.

J Pharmacol Exp Ther. 1997 Jan;280(1):210-9.

24.
25.

Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.

Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ.

Mol Pharmacol. 1996 Oct;50(4):891-9.

PMID:
8863835
26.

Evaluation of human cytokine production and effects of pharmacological agents in a heterologous system in vivo.

Griswold DE, Hillegass LM, O'Leary-Bartus J, Lee JC, Laydon JT, Torphy TJ.

J Immunol Methods. 1996 Sep 9;195(1-2):1-5.

PMID:
8814313
27.

Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding.

Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, Torphy TJ.

Biochem Pharmacol. 1996 Apr 12;51(7):949-56.

PMID:
8651945
28.

Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B.

Manning CD, McLaughlin MM, Livi GP, Cieslinski LB, Torphy TJ, Barnette MS.

J Pharmacol Exp Ther. 1996 Feb;276(2):810-8.

PMID:
8632354
29.
30.

Cysteinyl leukotrienes in asthma: old mediators up to new tricks.

Hay DW, Torphy TJ, Undem BJ.

Trends Pharmacol Sci. 1995 Sep;16(9):304-9. Review.

PMID:
7482995
31.
32.

Characterization of two human cAMP-specific phosphodiesterase subtypes expressed in baculovirus-infected insect cells.

Amegadzie BY, Hanning CR, McLaughlin MM, Burman M, Cieslinski LB, Livi GP, Torphy TJ.

Cell Biol Int. 1995 Jun;19(6):477-84.

PMID:
7640661
33.

The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.

Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ.

J Pharmacol Exp Ther. 1995 May;273(2):674-9.

PMID:
7752069
34.

Inhibitors of CoA-independent transacylase block the movement of arachidonate into 1-ether-linked phospholipids of human neutrophils.

Chilton FH, Fonteh AN, Sung CM, Hickey DM, Torphy TJ, Mayer RJ, Marshall LA, Heravi JD, Winkler JD.

Biochemistry. 1995 Apr 25;34(16):5403-10.

PMID:
7727398
35.

Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.

Torphy TJ, Barnette MS, Hay DW, Underwood DC.

Environ Health Perspect. 1994 Dec;102 Suppl 10:79-84.

36.

Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma.

Torphy TJ.

Trends Pharmacol Sci. 1994 Oct;15(10):370-4. Review.

PMID:
7809952
37.

A Candida albicans cyclic nucleotide phosphodiesterase: cloning and expression in Saccharomyces cerevisiae and biochemical characterization of the recombinant enzyme.

Hoyer LL, Cieslinski LB, McLaughlin MM, Torphy TJ, Shatzman AR, Livi GP.

Microbiology. 1994 Jul;140 ( Pt 7):1533-42.

PMID:
8075796
38.

Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.

Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW, Torphy TJ.

J Pharmacol Exp Ther. 1994 Jul;270(1):250-9.

PMID:
8035322
39.

Differential antagonism of airway contractile responses to prostaglandin (PG)D2 and 9 alpha, 11 beta-PGF2 by atropine, SK&F 88046 and SQ 29,548 in the guinea pig.

Underwood DC, Muccitelli RM, Luttmann MA, Hay DW, Torphy TJ, Wasserman MA.

J Pharmacol Exp Ther. 1994 Jan;268(1):304-10.

PMID:
8301572
40.

The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one.

Baures PW, Eggleston DS, Erhard KF, Cieslinski LB, Torphy TJ, Christensen SB.

J Med Chem. 1993 Oct 29;36(22):3274-7.

PMID:
8230117
41.

Association between leukotriene B4-induced phospholipase D activation and degranulation of human neutrophils.

Zhou HL, Chabot-Fletcher M, Foley JJ, Sarau HM, Tzimas MN, Winkler JD, Torphy TJ.

Biochem Pharmacol. 1993 Jul 6;46(1):139-48.

PMID:
8394074
42.

Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.

Underwood DC, Osborn RR, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, Torphy TJ.

J Pharmacol Exp Ther. 1993 Jul;266(1):306-13.

PMID:
8392555
43.

Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil.

Fonteh AN, Winkler JD, Torphy TJ, Heravi J, Undem BJ, Chilton FH.

J Immunol. 1993 Jul 1;151(1):339-50.

PMID:
8392098
44.

Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle.

Torphy TJ, Undem BJ, Cieslinski LB, Luttmann MA, Reeves ML, Hay DW.

J Pharmacol Exp Ther. 1993 Jun;265(3):1213-23.

PMID:
8389856
45.

Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.

Griswold DE, Webb EF, Breton J, White JR, Marshall PJ, Torphy TJ.

Inflammation. 1993 Jun;17(3):333-44.

PMID:
7687237
47.

Biochemical characteristics and cellular regulation of phosphodiesterase IV.

Torphy TJ, DeWolf WE Jr, Green DW, Livi GP.

Agents Actions Suppl. 1993;43:51-71. Review.

PMID:
8396319
48.
49.
50.

Agonist-related differences in the relationship between cAMP content and protein kinase activity in canine trachealis.

Zhou HL, Newsholme SJ, Torphy TJ.

J Pharmacol Exp Ther. 1992 Jun;261(3):1260-7.

PMID:
1318375

Supplemental Content

Loading ...
Support Center